MTHFR and hematologic disorder: The evidence-based practice guideline of HDMTX medication of the Chinese Pharmacological Society (Wang et al., 2021) states that the genotyping of MTHFR 677C>T and 1298A>C polymorphisms can be considered for patients with hematological malignancies (weak recommendation, moderate quality evidence), and the genotyping of ABCB1 3435C>T may be considered under certain conditions (weak recommendation, low-quality evidence).